Free Trial
NASDAQ:MDGL

Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis

Madrigal Pharmaceuticals logo
$436.28 -6.03 (-1.36%)
Closing price 10/7/2025 04:00 PM Eastern
Extended Trading
$446.27 +9.99 (+2.29%)
As of 10/7/2025 05:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Madrigal Pharmaceuticals Stock (NASDAQ:MDGL)

Advanced

Key Stats

Today's Range
$433.00
$444.14
50-Day Range
$289.88
$458.66
52-Week Range
$200.63
$463.63
Volume
235,679 shs
Average Volume
304,314 shs
Market Capitalization
$9.69 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$495.88
Consensus Rating
Moderate Buy

Company Overview

Madrigal Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
86th Percentile Overall Score

MDGL MarketRank™: 

Madrigal Pharmaceuticals scored higher than 86% of companies evaluated by MarketBeat, and ranked 143rd out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Madrigal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 9 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Madrigal Pharmaceuticals has a consensus price target of $495.88, representing about 13.7% upside from its current price of $436.28.

  • Amount of Analyst Coverage

    Madrigal Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Madrigal Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($23.47) to ($12.00) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Madrigal Pharmaceuticals is -33.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Madrigal Pharmaceuticals is -33.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Madrigal Pharmaceuticals has a P/B Ratio of 12.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Madrigal Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    18.65% of the outstanding shares of Madrigal Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Madrigal Pharmaceuticals has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Madrigal Pharmaceuticals has recently increased by 2.22%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Madrigal Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Madrigal Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    18.65% of the outstanding shares of Madrigal Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Madrigal Pharmaceuticals has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Madrigal Pharmaceuticals has recently increased by 2.22%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Madrigal Pharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 17 news articles for Madrigal Pharmaceuticals this week, compared to 10 articles on an average week.
  • Search Interest

    6 people have searched for MDGL on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Madrigal Pharmaceuticals insiders have sold 82.01% more of their company's stock than they have bought. Specifically, they have bought $61,921,142.00 in company stock and sold $112,705,072.00 in company stock.

  • Percentage Held by Insiders

    21.50% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    98.50% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Madrigal Pharmaceuticals' insider trading history.
Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MDGL Stock News Headlines

Financial markets news icon
MarketBeat Week in Review – 09/08 - 09/12 (MDGL)
Markets had another strong week as inflaton data set the stage for the Federal Reserve’s meeting next week; a rate cut is expected but may already be priced in...
Insider Trading written on a stock ticker
CoreWeave and Madrigal's Insider Trades Flash Bullish Signals (MDGL)
Insider trades at NVIDIA-backed CoreWeave and Madrigal Pharmaceuticals are bullish indicators, but for very different reasons.
Forget AI, This Will Be the Next Big Tech Breakthrough
After picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be the biggest paradigm shift ever. Yes, even bigger than AI. And he found one Seattle company that's at the center of this new $100 trillion revolution. Click here to get the name of this company, completely free of charge...tc pixel
Q3 Earnings Forecast for MDGL Issued By B. Riley
See More Headlines

MDGL Stock Analysis - Frequently Asked Questions

Madrigal Pharmaceuticals' stock was trading at $308.57 at the start of the year. Since then, MDGL stock has increased by 41.4% and is now trading at $436.28.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) released its quarterly earnings results on Tuesday, August, 5th. The biopharmaceutical company reported ($1.90) EPS for the quarter, topping the consensus estimate of ($3.48) by $1.58. The firm's revenue was up 1357.5% on a year-over-year basis.
Read the conference call transcript
.

Madrigal Pharmaceuticals' top institutional shareholders include Praxis Investment Management Inc. and GAMMA Investing LLC. Insiders that own company stock include Bros Advisors Lp Baker, Rebecca Taub, Paul A Friedman, William John Sibold, Brian Joseph Lynch, Richard S Levy, Fred B Craves, Carole Huntsman, Shannon T Kelley, Robert E Waltermire, Kenneth Bate, James M Daly and Remy Sukhija.
View institutional ownership trends
.

Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Madrigal Pharmaceuticals investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Humana (HUM) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
8/05/2025
Today
10/07/2025
Next Earnings (Estimated)
10/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MDGL
CIK
1157601
Employees
90
Year Founded
2011

Price Target and Rating

High Price Target
$560.00
Low Price Target
$350.00
Potential Upside/Downside
+13.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
($12.85)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$465.89 million
Net Margins
-54.68%
Pretax Margin
-54.68%
Return on Equity
-38.38%
Return on Assets
-27.32%

Debt

Debt-to-Equity Ratio
0.17
Current Ratio
5.11
Quick Ratio
4.78

Sales & Book Value

Annual Sales
$180.13 million
Price / Sales
53.77
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$34.59 per share
Price / Book
12.61

Miscellaneous

Outstanding Shares
22,200,000
Free Float
17,429,000
Market Cap
$9.69 billion
Optionable
Optionable
Beta
-1.02

Social Links

10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:MDGL) was last updated on 10/8/2025 by MarketBeat.com Staff
From Our Partners